Macrophages heterogeneity in atherosclerosis - implications for therapy.
about
Effects of chalcone derivatives on players of the immune systemVitamin D deficiency induces high blood pressure and accelerates atherosclerosis in miceAn integrated microfluidic device for monitoring changes in nitric oxide production in single T-lymphocyte (Jurkat) cells.SOCS1 regulates the immune modulatory properties of mesenchymal stem cells by inhibiting nitric oxide production.The influence of ezetimibe on classical and alternative activation pathways of monocytes/macrophages isolated from patients with hypercholesterolemia.Diabetes alters activation and repression of pro- and anti-inflammatory signaling pathways in the vasculature.Non-viral nanoparticle delivers small interfering RNA to macrophages in vitro and in vivo.Anti-inflammatory and antioxidant activities of the nonlipid (aqueous) components of sesame oil: potential use in atherosclerosisSplice variants of tissue factor promote monocyte-endothelial interactions by triggering the expression of cell adhesion molecules via integrin-mediated signaling.Heme oxygenase-1, oxidation, inflammation, and atherosclerosisIntimal lining layer macrophages but not synovial sublining macrophages display an IL-10 polarized-like phenotype in chronic synovitisInducible renitence limits Listeria monocytogenes escape from vacuoles in macrophages.Recent Advances in Targeted, Self-Assembling Nanoparticles to Address Vascular Damage Due to Atherosclerosis.Hepcidin-ferroportin axis controls toll-like receptor 4 dependent macrophage inflammatory responses in human atherosclerotic plaquesPreclinical mouse models and methods for the discovery of the causes and treatments of atherosclerosisTargeting and therapeutic peptides in nanomedicine for atherosclerosis.Percutaneous Transluminal Angioplasty in Patients with Peripheral Arterial Disease Does Not Affect Circulating Monocyte Subpopulations.Nicotine potentiates proatherogenic effects of oxLDL by stimulating and upregulating macrophage CD36 signaling.A critical role for suppressor of cytokine signalling 3 in promoting M1 macrophage activation and function in vitro and in vivoMacrophages and CSF-1: implications for development and beyondInflammation in atherosclerosis: a cause or a result of vascular disorders?Particulate systems for targeting of macrophages: basic and therapeutic concepts.Targeting macrophage subsets for infarct repair.A focus on inflammation as a major risk factor for atherosclerotic cardiovascular diseases.Surface modification of nanoparticles enables selective evasion of phagocytic clearance by distinct macrophage phenotypes.Human monocyte-derived macrophages spontaneously differentiated in vitro show distinct phenotypes.Cytokine Disturbances in Coronary Artery Ectasia Do Not Support Atherosclerosis Pathogenesis.Peroxisome proliferator-activated receptor γ (PPARγ): A master gatekeeper in CNS injury and repair.Regulatory T cells as a new therapeutic target for atherosclerosis.CD80 Is Upregulated in a Mouse Model with Shear Stress-Induced Atherosclerosis and Allows for Evaluating CD80-Targeting PET Tracers.Macrophage Polarization in Chronic Inflammatory Diseases: Killers or Builders?2-arachidonoylglycerol levels are increased in leukocytospermia and correlate with seminal macrophages.Comparison of fluorodeoxyglucose uptake in symptomatic carotid artery and stable femoral artery plaques.Suppressor of cytokine signaling (SOCS)1 is a key determinant of differential macrophage activation and function.
P2860
Q26796454-5BC8E3FC-0E5E-48E3-8567-50CE22096206Q27318595-61748F6D-3784-4C91-A24F-183829B958E1Q30573981-5DB33C41-B5F7-425C-8698-423BAC20E0A2Q31161219-9508D6D4-FFBE-40A6-844E-F9B02D6B2841Q33883204-D20E4BD3-9410-4E69-912C-6861EB8F5C9FQ34350546-C85A56E1-A934-4E8A-B573-63E019EE61EAQ35208236-6A73DCBD-62E4-40B3-9F4E-64432A7B7471Q35324991-157C06AA-B87A-4A8A-B86A-49936DB386C3Q35797625-478E5765-5654-428F-BD34-DFB6E8D26668Q36103851-4F06E5F8-0CE0-439E-B9D7-BAF4AF0326B1Q36245798-EDBEA4F9-A437-49D5-B603-A85FD686C833Q36339378-1F89113D-889F-4831-83D0-B0A6F859CEA2Q36598388-0B320F82-3964-44A3-A458-3051A12E2820Q36698180-3718748D-A28E-4DBD-9215-217C781430BCQ36728741-96721E75-D8C4-4E2A-A2D4-1AA42A06767FQ36913594-DB70E333-77DA-40D2-B034-93A572D551D4Q37368874-00562565-8614-47B5-B598-106F6E1A72D9Q37476547-C325724A-10BD-4FF4-963F-0D4BE181091BQ37486900-044C1A7C-74A2-46BF-AD74-690EDE718A3EQ37521345-98B894F9-5EF9-4883-96E2-8A155EAEE094Q37986175-81EFD600-5F98-443C-933A-C4234BEF519EQ38020769-9FD5E06A-B31C-42B7-A679-92B69D848660Q38221014-98E1D421-02DF-4997-A794-7A5636FA11A2Q38660995-030BA67D-C25D-407C-A7A0-C7C89BC89E8DQ42565911-1C512EE5-7CC5-4AF8-936A-20226E740497Q43426879-F90949D6-B76B-447F-B382-1A661CFCF3A4Q47552834-3F4E6011-C9BE-4BC4-AAD3-F4610434F0C7Q47739408-6F1F5CA3-3540-4389-AE75-55B04CF105AFQ50093330-98EEBB07-B238-4563-AE7D-64184956974AQ51633536-33785A68-5717-4718-96D7-F449DA3DC4FCQ52672848-B08B0889-DE15-424F-B9AA-D77528F1D1ACQ52959149-4BE77146-0C5B-446E-B4D3-27E841AA964CQ53065955-F047506B-4804-477A-9221-CBECAAE28F7FQ53243987-8030C53C-E610-4CAB-82A1-62EB873F4998
P2860
Macrophages heterogeneity in atherosclerosis - implications for therapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 12 July 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Macrophages heterogeneity in atherosclerosis - implications for therapy.
@en
Macrophages heterogeneity in atherosclerosis - implications for therapy.
@nl
type
label
Macrophages heterogeneity in atherosclerosis - implications for therapy.
@en
Macrophages heterogeneity in atherosclerosis - implications for therapy.
@nl
prefLabel
Macrophages heterogeneity in atherosclerosis - implications for therapy.
@en
Macrophages heterogeneity in atherosclerosis - implications for therapy.
@nl
P2860
P921
P1476
Macrophages heterogeneity in atherosclerosis - implications for therapy
@en
P2093
Heather M Wilson
P2860
P304
P356
10.1111/J.1582-4934.2010.01121.X
P577
2010-07-12T00:00:00Z